Venus Remedies News

Venus Remedies AGM: Dividend, Board Changes

Venus Remedies Limited convenes its 37th AGM on August 20, 2026, to approve a ₹10 dividend and appoint new directors. The meeting also seeks ratification of cost auditor fees and amendments to the MOA.

Venus Remedies Q1 net profit rises 118% YoY

Venus Remedies reported a consolidated net profit of ₹22.97 crore for Q1FY26, up from ₹9.60 crore in the year-ago period. Revenue from operations increased to ₹178.86 crore.

Venus Remedies declares ₹10 dividend

Venus Remedies Limited has announced a final dividend of ₹10 per share for FY26. The company set August 7, 2026, as the record date for determining shareholder eligibility.

Venus Remedies FY26 net profit rises 89% to ₹102.78 crore

Venus Remedies reported a consolidated net profit of ₹102.78 crore for FY26, up from ₹45.31 crore in the previous year. The board recommended a final dividend of ₹10 per share and scheduled the AGM for August 20, 2026.

Venus Remedies Gets Saudi FDA Nod for Plerixafor

Venus Remedies secures Saudi FDA approval for Plerixafor, marking its first global marketing authorization for this specialty cancer treatment.